AGŐćČ˹ٷ˝

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCLI
  4. [8-K] Brainstorm Cell Therapeutics Inc. Reports Material Event

[8-K] Brainstorm Cell Therapeutics Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock BCLI logo
Brainstorm Cell Therapeutics I

NASDAQ:BCLI

BCLI Rankings

#9743 Ranked by Market Cap
N/A Ranked by Dividends
#2 Top Loser

BCLI Latest News

Jul 17, 2025
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
Jul 8, 2025
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
Jun 16, 2025
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®
May 27, 2025
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
May 19, 2025
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

BCLI Latest SEC Filings

Jul 3, 2025
[S-8] Brainstorm Cell Therapeutics Inc. Employee Benefit Plan Registration
Jun 25, 2025
[S-3] Brainstorm Cell Therapeutics Inc. Shelf Registration Statement
Jun 25, 2025
[8-K] Brainstorm Cell Therapeutics Inc. Reports Material Event

BCLI Stock Data

12.20M
6.67M
20.84%
12.49%
1.88%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
NEW YORK